tbuckley/cabot-search huggingface dataset:
THE SAFETY OF DISCONTINUATION OF LONG-TERM ORAL ANTICOAGULATION THERAPY AFTER APPARENTLY SUCCESSFUL ATRIAL FIBRILLATION ABLATION: CHINESE ATRIAL FIBRILLATION REGISTRY STUDY
Authors: Wangyang Yang, Xin Du, Nian Liu, Rong Bai, Wei Wang, Liu He, Lu Wang, Chang Liu, Xueyuan Guo, Songnan Li, Caihua Sang, Chenxi Jiang, Ronghui Yu, Deyong Long, Jianzeng Dong, Changsheng Ma
Journal: Journal of the American College of Cardiology (2018)
Watching the English
Authors: Lenny Ng
Journal: BMJ (2007)

We are accustomed to not saying what we mean: irony, self deprecation, understatement, obliqueness, ambiguity, and polite pretence are all deeply ingrained—it's part of being English.

If someone had given me this book when I first arrived in England to study medicine, it would have saved lots of time attempting to decode England's mysterious ways.

I would have appreciated that awkwardness and embarrassment at social interactions were a feature of the English “social dis-ease”; that incessant moaning about almost everything was not a result of discontent, but …
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy
Authors: C.A. Morton, R. Dominicus, P. Radny, T. Dirschka, A. Hauschild, U. Reinhold, R. Aschoff, M. Ulrich, S. Keohane, S. Ekanayake-Bohlig, S. Ibbotson, R. Ostendorf, C. Berking, D. Gröne, H.J. Schulze, H.M. Ockenfels, V. Jasnoch, H. Kurzen, M. Sebastian, H. Stege, P. Staubach, G. Gupta, F. Hübinger, I. Ziabreva, B. Schmitz, A. Gertzmann, H. Lübbert, R.-M. Szeimies
Journal: British Journal of Dermatology (2018)

Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants of the latter are primary nodular and superficial BCC.To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL (a cream containing methyl aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic therapy (PDT). Noninferiority of the primary efficacy variable (overall patient complete response 12 weeks after last PDT) would be declared if the mean response for BF-200 ALA was no worse than that for MAL, within a statistical margin of Δ = -15%.The study was a randomized, phase III trial performed in Germany and the U.K. with ongoing 5-year follow-up. Of 281 randomized patients, 138 were treated with BF-200 ALA and 143 with MAL. Patients received two PDT sessions 1 week apart. Remaining lesions 12 weeks after the second PDT were retreated. Illumination was performed with a red light source (635 nm, 37 J cm-2 ). The results shown include clinical end points and patients' reassessment 12 months after the last PDT. The study was registered with EudraCT (number 2013-003241-42).Of the BF-200 ALA-treated patients, 93·4% were complete responders compared with 91·8% in the MAL group. The difference of means was 1·6, with a one-sided 97·5% confidence interval of -6·5, establishing noninferiority (P < 0·0001). The results for secondary efficacy parameters were in line with the primary outcome. Recurrence rates 12 months after the last treatment were ≤ 10%.Treatment of nonaggressive BCC with BF-200 ALA-PDT is highly effective and well tolerated with proven noninferiority to MAL-PDT. It demonstrates low recurrence rates after 1 year of follow-up.
TREATMENT WITH TETRAHYDROBIOPTERIN ACCELERATES WHITE MATTER MATURATION IN A MOUSE MODEL OF PRENATAL HYPOXIA SIMULATING CONGENITAL HEART DISEASE
Authors: Jennifer Romanowicz, Ludmila Korotcova, Shruti D. Ramachandra, Paul D. Morton, Amrita Cheema, Vittorio Gallo, Richard A. Jonas, Nobuyuki Ishibashi
Journal: Journal of the American College of Cardiology (2018)
General practice in the United Kingdom
Authors: Roopa Venktesh
Journal: BMJ (2005)

www.gprecruitment.org.uk

www.pgmd.man.ac.uk

www.jcptgp.org.uk

www.gmc-uk.org

www.rcgp.org.uk

www.gpnotebook.co.uk



The internet is probably the easiest way to find information on a career in general practice in the United Kingdom. The national recruitment office coordinates recruitment to general practice schemes throughout England, Wales, and Northern Ireland. The website www.gprecruitment.org.uk is designed to help doctors who want to train for general practice to identify available opportunities and make informed judgments about where they wish to train. It includes eligibility requirements, deanery information, and the answers to the most frequently asked questions. …
Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT
Authors: Qingqing Pan, Yaping Luo, Xinxin Cao, Yanru Ma, Fang Li
Journal: Clinical Nuclear Medicine (2018)

A 60-year-old woman diagnosed with multiple myeloma was referred for Ga-pentixafor PET/CT for evaluation of the disease. Diffuse and intense radioactivity throughout the axial and proximal appendicular skeleton was noted on PET/CT images, suggestive of extensive involvement of multiple myeloma.
Diploma in genitourinary medicine
Authors: Macky Natha
Journal: BMJ (2005)

Who is it for? For specialist registrars in genitourinary medicine (GUM) (and compulsory by end of year 2), other trainees in GUM (non-consultant career grade doctors, senior house officers, staff grades, clinical assistants), general practitioners with a special interest. It is also taken by overseas practitioners.

When did you do it? In June 2004, at the end of year 2 of specialist …
Junior doctors call on peers to engage with details of new contract
Authors: Abi Rimmer
Journal: BMJ (2016)

Junior doctors have called on their peers to read and engage with the details of the new terms and conditions agreed by the BMA and the government last month

On Friday 27 May, NHS Employers published the full terms and conditions of service for NHS doctors and dentists in training in England.1 On the same day, the Department of Health published an equalities statement for the proposed new contract.2

The publications came after the Advisory, Conciliation and Arbitration Service (Acas) announced on 18 May that an agreement on the contract had been reached between the BMA and the government.3

Rachel Clarke, a second year core trainee in infectious diseases, said that the new proposals were an improvement on offers that had previously been made. “The BMA …
Abstract P131: Influence of PNPLA3 Interaction With Physical Activity and Dietary Pattern on Hepatic Steatosis Among African Americans in the Jackson Heart Study
Authors: Stanford E Mwasongwe, Jiankang Liu, Hannah Scott, Mario Sims, Adolfo Correa, Solomon K Musani
Journal: Circulation (2018)

Background: The genetic basis for nonalcoholic fatty liver disease (NAFLD) has been studied widely. Several common variants near genes known to be associated with NAFLD have been identified and replicated across ancestries. The extent to which these variants interact with lifestyles factors, particularly in African Americans (AAs) is unknown. We hypothesized that physical activity and dietary pattern moderate the association of patatin-like phospholipase domain containing 3 ( PNPLA3 ) variant rs738409 with NAFLD. Methods: Of the 2,884 Jackson Heart Study participants with hepatic steatosis measured by computed tomography, a subset of 1,075 were part of a family study and another set of 1,583 were genotyped for common genetic variants near PNPLA3 . We estimated polygenic heritability of hepatic steatosis (inverse normally transformed) using a variance components approach implemented in SOLAR controlling for variations in age, age 2 , gender and alcoholic drinks. To evaluate moderation effect of rs738409 by diet and physical activity, we analyzed genotyped individual using multiple linear regression and controlled for population structure in addition to covariates included in estimating heritability. Dietary pattern was defined using principal components analysis while physical activity according to AHA categorization. Results: The polygenic heritability estimate of hepatic steatosis in our study was 0.33±0.09 (p&lt;0.001). The G allele of the rs738409 variant (allele frequency 14%) was significantly (beta ± standard error; p-value) associated with high hepatic steatosis in participants who are physically inactive (0.29±0.12; 0.0169) and those with unhealthy dietary pattern (0.25±0.10; 0.0144) ( Figure) . Conclusions: In a community-based cohort of AA, heritability of hepatic steatosis is moderate and compares favorably with previous estimates. Physical activity and diet modulates the effect of PNPLA3 : rs738409 on NALFD. The role lifestyle factors on NAFLD need to be validated in other population samples.
I have just passed my membership and have applied for a locum job as a staff grade (as an NHS locum, paying monthly). If I continue to work for up to three months at this job, will my basic salary be protected as an SpR?
Authors: Adam Harrison
Journal: BMJ (2006)

Have a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site. <b>www.bmjcareers.com/advicezone</b>
Integrative transcriptional analysis of enzalutamide-resistant castration resistant prostate cancer cells using RNA sequencing.
Authors: Tae Heon Kim, Minyong Kang, Ji Youn Oh, Yumi Kang
Journal: Journal of Clinical Oncology (2018)

284 Background: Enzalutamide (ENZ)-resistance is a clinically challaengeable issue for management of castration-resistant prostate cancer (CRPC) patients. Here, we aimed to investigate the distinct features of transcriptional expression in ENZ-resistant CRPC cells using RNA sequencing, focusing on the histone modification enzymes as AR co-regulators. Methods: We chronically treated various concentration of ENZ (1 to 40 µM) for 6 to 9 months to establish ENZ-resistant CRPC cells by using C4-2B cells. To explore the phenotypic features of ENZ-resistant CRPC cells (ENZ-R), we analyzed the gene expression patterns, particularly AR target genes, following ENZ treatment. We performed cell viability assay, clonogenic assay, apotosis assay and tumor sphere formation assay. To examine the distinct features of transcriptional expression in ENZ-resistant CRPC cells, we conducted RNA sequencing and classified the key differential expression genes (DEG) according to Gene Ontology Database. Results: ENZ-R cells showed a higher cell viability and clonogenic proliferation compared to control cells following ENZ treatment. Also, ENZ-R cells showed higher gene expression of AR target gens (KLK2, KLK3, TTMPRSS) than those in control cells after dihydrotestosterone treatment. Of note, ENZ-R cells significantly expressed full length AR as well as AR splicing variant 7. Moreover, RNA sequencing revealed that 367 up-regulated genes and 223 down-regulated genes were identified as DEG compared to control cells. We further analyzed these DEG of histone modification enzyme as AR co-regulators, and therefore; we finally determined the candidate 28 target genes of histone modification enzyme (23 up-regulated and 5 down-regulated genes). We validated the differential expression of these key histone modification enzyme genes in ENZ-R cells by using real-time PCR. Conclusions: In sum, we established the ENZ-R cells and identified the 28 candidate DEG of histone modification enzyme in ENZ-R cells by performing RNA sequencing analysis. Our study can offer the valuable information for exploring the ENZ-resistant mechanisms, particularly focusing on the imbalance of AR co-regulators.
Only one in 10 new GPs get a partnership on qualification
Authors: Helen Jaques
Journal: BMJ (2012)

Only 10% of new GPs in the BMA’s cohort study of medical graduates secured a GP partnership post on receipt of their certificate of completion of training (CCT) last summer.

Nine of the 91 newly qualified GPs followed by the BMA throughout their training since graduation from medical school in 2006 were in a partnership post as of August 2011, when they had completed GP training. 

The GPs in the cohort were most likely to be working as a salaried GP (34%) or a locum (22%) once they were awarded their CCT in August …
I am applying for a salaried GP post. However, I have found out that I am nine weeks' pregnant with my first baby. Should I tell my new employer before signing any contracts (I know that legally I am not obliged to tell them yet), or can I wait until I have had the first dating scan?
Authors: Kay Mohanna
Journal: BMJ (2005)

Have a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site. <b>www.bmjcareers.com/advicezone</b>
Robotic-Assisted vs Laparoscopic Radical Nephrectomy—Reply
Authors: In Gab Jeong, Yash S. Khandwala, Benjamin I. Chung
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunotherapy use, outcomes, and toxicities in gastrointestinal malignancies.
Authors: Rachel Julie David, Andrea Baran, Ronald John Maggiore
Journal: Journal of Clinical Oncology (2018)

100 Background: Use of checkpoint inhibitors has expanded over recent years, and the gastrointestinal (GI) oncologic indications for immunotherapy (IO) continue to evolve. IO use in GI malignancies is still in its infancy, and we sought to describe our clinical experience thus far. Methods: We retrospectively identified all patients (pts) with GI malignancies treated with IO at the Wilmot Cancer Institute from December, 2015 through July, 2017. We examined patient and tumor-related clinicopathologic features. Our main outcomes of interest were best response on IO, and frequency/severity of IO toxicity. Fisher’s exact test was used to compare categorical factors between groups of interest. Results: 21 pts received IO for a GI malignancy, all of whom had metastases (mets). 76% of pts were male, and the median age was 62 years (range, 25 – 87). Common diagnoses were colorectal (CRC) (n = 10), gastroesophageal (GE) (n = 5), and hepatocellular cancers (HCC) (n = 4). 76% of pts received pembrolizumab, and 24% of pts received nivolumab. 67% received IO as ≥ 3 rd -line therapy. The median time from diagnosis of metastatic disease to initiation of IO was 17.8 mos (range, 3 – 140). The median time on therapy was 2.62 months (95% CI 1.48, 6.52 mos) (range, 0.5 – 11 mos), with 3 pts still responding at the time of the analysis. Pts with HCC had the longest time on IO (8.95 mos), compared to 2.62 mos for GE, 2.39 mos for CRC, and 1.26 mos for all other (p = 0.10). Pts who received IO as 3 rd or greater line of therapy had a significantly increased likelihood of non-response or progressive disease/death compared to pts who received IO as 2 nd -line (p = 0.02). There was a trend towards non-response to IO in pts with liver mets vs. extrahepatic mets (p = 0.09). 57% experienced grade 3/4 toxicities: the most common were anemia (24%), hyponatremia (14%), and fatigue (14%). No IO-specific grade 3/4 immune-related toxicities were observed. Conclusions: The majority of our pts received IO as 3 rd line therapy or beyond, and were significantly less likely to respond to treatment compared to those who received IO earlier on. The presence of liver mets is potentially associated with non-response to IO, and needs further exploration. No unexpected or severe IO-related toxicities were observed.
OUTCOMES OF PATIENTS WITH SMALL VESSELS UNDERGOING PCI WITH CONTEMPORARY DRUG-ELUTING STENTS: A SUB-ANALYSIS FROM THE BIONICS STUDY
Authors: Maayan Konigstein, David Kandzari, Gidon Perlman, Michael Love, Pieter Smits, Shmuel Banai, Ozan Melek Ozgu, Martin B. Leon, Gregg Stone, Ori Ben-Yehuda
Journal: Journal of the American College of Cardiology (2018)
Assisted dying: it’s time to poll UK doctors
Authors: Fiona Godlee
Journal: BMJ (2018)

Doctors’ organisations provide crucial leadership, cohesion, a community, resources, and support for their members. They also speak for the profession; their positions on ethical issues are therefore of great importance to national debate. The BMA and the key medical royal colleges remain opposed to assisted dying. So too do the American Medical Association, the American College of Physicians, and the American Academy of Family Physicians, despite assisted dying being legally available to 58 million Americans in six states and the District …
Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver
Authors: Ruben Bill, Matteo Montani, Benedikt Blum, Jean‐François Dufour, Robert Escher, Michael Bühlmann
Journal: Hepatology (2018)

Bill, Ruben; Montani, Matteo; Blum, Benedikt; Dufour, Jean‐François; Escher, Robert; Bühlmann, Michael Author Information
Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes
Authors: Zobair M. Younossi, Maria Stepanova, Harry L.A. Janssen, Kosh Agarwal, Mindie H. Nguyen, Ed Gane, Naoky Tsai, Issah Younossi, Andrei Racila
Journal: Clinical Gastroenterology and Hepatology (2018)
ABNORMAL LEFT ATRIAL MECHANICS PREDICT INCIDENT ATRIAL FIBRILLATION IN AL CARDIAC AMYLOIDOSIS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
Authors: Graham Lohrmann, Monica Arun, Dina Brauneis, Karen Quillen, Vaishali Sanchorawala, Shayna Sarosiek, Omar Siddiqi, Frederick Ruberg, Deepa Gopal
Journal: Journal of the American College of Cardiology (2018)
CLINICAL IMPACT OF DIRECT STENTING AND INTERACTION WITH THROMBUS ASPIRATION IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: THROMBECTOMY TRIALISTS COLLABORATION
Authors: Karim D. Mahmoud, Sanjit Jolly, Stefan James, Vladimir Dzavik, John Cairns, Salim Yusuf, Goran Olivecrona, Henrik Renlund, Peggy Gao, Bo Lagerqvist, Ashraf Alazzoni, Sasko Kedev, Goran Stankovic, Brandi Meeks, Ole Frobert, Felix Zijlstra
Journal: Journal of the American College of Cardiology (2018)
Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension
Authors: Elsayed Z. Soliman, Walter T. Ambrosius, William C. Cushman, Zhu-ming Zhang, Jeffrey T. Bates, Javier A. Neyra, Thaddeus Y. Carson, Leonardo Tamariz, Lama Ghazi, Monique E. Cho, Brian P. Shapiro, Jiang He, Lawrence J. Fine, Cora E. Lewis
Journal: Circulation (2017)

It is currently unknown whether intensive blood pressure (BP) lowering beyond that recommended would lead to more lowering of the risk of left ventricular hypertrophy (LVH) in patients with hypertension and whether reducing the risk of LVH explains the reported cardiovascular disease (CVD) benefits of intensive BP lowering in this population.
A systematic classification of death causes in multiple myeloma
Authors: Elias K. Mai, Eva-Maria Haas, Stephan Lücke, Martin Löpprich, Christina Kunz, Maria Pritsch, Petra Knaup-Gregori, Marc S. Raab, Jana Schlenzka, Uta Bertsch, Jens Hillengass, Hartmut Goldschmidt
Journal: Blood Cancer Journal (2018)
Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas
Authors: Jean‐Charles Nault, Gabrielle Couchy, Stefano Caruso, Léa Meunier, Laure Caruana, Eric Letouzé, Sandra Rebouissou, Valérie Paradis, Julien Calderaro, Jessica Zucman‐Rossi
Journal: Hepatology (2018)

Genetic alterations define different molecular subclasses of hepatocellular adenoma (HCA) linked with risk factors, histology and clinical behavior. Recently, Argininosuccinate Synthase 1 (ASS1), a major periportal protein, was proposed as a marker of HCA with a high risk of hemorrhage. We aimed to assess the significance of ASS1 expression through the scope of the HCA molecular classification. ASS1 expression was evaluated using RNAseq, quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and Immunohistochemistry. ASS1 and glioma-associated oncogene 1 (GLI1) expression were analyzed in vitro after modulation of GLI1 expression. Using RNAseq in 27 HCA and five nontumor liver samples, ASS1 expression was highly correlated with GLI1 expression (P<0.0001, R=0.75). In the overall series of 408 HCA, ASS1 overexpression was significantly associated with sonic hedgehog HCA (shHCA) compared to other molecular subgroups (P<0.0001), suggesting that sonic hedgehog signaling controls ASS1 expression. GLI1 expression silencing by siRNA induced a downregulation of ASS1 in PLC/PFR5 and SNU878 cell lines. In 390 HCA, we showed that ASS1 expression belonged to the periportal expression program that was maintained in shHCA but down-regulated in all the other HCA subtypes. In contrast, HCA with β-catenin activation showed an activation of a perivenous program. Despite the significant association between GLI1 and ASS1 expression, ASS1 mRNA expression was not associated with specific clinical features. At the protein level using immunohistochemistry, prostaglandin D synthase (PTGDS) was strongly and specifically overexpressed in shHCA.ASS1 is associated with sonic hedgehog activation as part of a periportal program expressed in shHCA, a molecular subgroup defined by INHBE-GLI1 gene fusion. (Hepatology 2018).